Suchergebnisse - "Verbinnen, Thierry"

PubPharm (6)

1

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1) : a multicentre, double-blind, active-controlled, randomised, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Yuen, M. | Asselah, T. | Jacobson, I. | +116

CommentIn: Lancet Gastroenterol Hepatol. 2023 Sep;8(9):772-773. - PMID 37442151

2

Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study

enthalten in: Antiviral research | 2023

von Verbinnen, T. | Talloen, W. | Janssen, H. | +6

3

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

enthalten in: Gut | 2023

von Janssen, H. | Hou, J. | Asselah, T. | +16

4

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Gane, E. | Schwabe, C. | Berliba, E. | +12

5

Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy

enthalten in: Journal of viral hepatitis | 2020

von Verbinnen, T. | Hodari, M. | Talloen, W. | +7

6

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Verbinnen, T. | Tan, Y. | Wang, G. | +6

1
[1]